Literature DB >> 8639431

Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.

L M Silla1, S M Pincus, J D Locker, J Glover, E M Elder, A D Donnenberg, N B Nardi, J Bryant, E D Ball, T L Whiteside.   

Abstract

Activated natural killer (A-NK) cells, a subset of CD56(dim)CD3- lymphocytes, are obtained from PBMC of normal donors by adherence to plastic and culture in the presence of IL2. In this study we tested the feasibility of generating A-NK cells in patients with Ph+ chronic myeloid leukaemia (CML). Cultures obtained from patients with early chronic phase (ECP; n=7) contained a mean (+/-SD) of83 +/- 7% of CD3- cells, and those from patients with advanced chronic phase (ACP; n=7) contained 27+/-33% CD56+CD3- cells. In three patients with leukaemia in a blastic phase (BP) it was only possible to obtain one culture enriched in CD56+CD3- cells (81%). Cellular aggregates of myeloid cells and large granular lymphocytes were observed in early A-NK cell cultures. Paired freshly-adherent and cultured A-NK cells were tested for the presence of BCR/abl mRNA by RT-PCR. The BCR/abl+ cells were detected in all 12 preparations of the freshly adherent A-NK cells tested. In 6/12 the BCR/abl+ cells were no longer detectable by RT-PCR on day 14 of culture. Both proliferation and antileukaemic cytotoxicity were significantly higher (P=0.002 and P=0.029, respectively) in the BCR/abl- cultures than those in the six BCR/abl+ cultures. 5/6 BCR/abl- cultures were highly enriched in A-NK cells on day 14, and 1/6 contained predominantly CD56+CD3+ cells. Only 2/6 BCR/abl + cultures were enriched in A-NK cells on day 14, but they had poor cytotoxicity and a low proliferative index. Myeloid cells (CD33+) were more frequently detected in the BCR/abl+ than BCR/abl- A-NK cell cultures (P=0.028). These observations suggest that: (1) populations of benign A-NK cells can be generated from the peripheral blood of CML patients; (2) the ability to generate A-NK cells is impaired in patients with advanced CML; and (3) the ability to generate A-NK cells with antileukaemic activity correlates with the disappearance of BCR/abl+ cells from these cultures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639431     DOI: 10.1046/j.1365-2141.1996.4991043.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.

Authors:  Hideo Tanaka; Shizuka Nakashima; Miyuki Usuda
Journal:  Int J Hematol       Date:  2012-07-06       Impact factor: 2.490

Review 2.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

3.  Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.

Authors:  Takashi Kumagai; Eri Matsuki; Koiti Inokuchi; Kazuteru Ohashi; Atsushi Shinagawa; Jin Takeuchi; Chikashi Yoshida; Shinichiro Okamoto; Hisashi Wakita; Yasuji Kozai; Yukari Shirasugi; Shin Fujisawa; Osamu Iwase; Shingo Yano; Kaichi Nishiwaki; Koji Oba; Junichi Sakamoto; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2013-12-03       Impact factor: 2.490

4.  Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.

Authors:  Dong Hwan Kim; Suzanne Kamel-Reid; Hong Chang; Robert Sutherland; Chul Won Jung; Hyeoung-Joon Kim; Je-Jung Lee; Jeffrey H Lipton
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941

5.  What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?

Authors:  Guilherme Rasia Bosi; Laura Maria Fogliatto; Tito Emilio Vanelli Costa; Kamila Castro Grokoski; Mariana Pinto Pereira; Nathan Bugs; Marco Kalil; Christina Fraga; Liane Esteves Daudt; Lucia Mariano da Rocha Silla
Journal:  Hematol Transfus Cell Ther       Date:  2019-03-28

Review 6.  Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.

Authors:  Mattias Carlsten; Marcus Järås
Journal:  Front Immunol       Date:  2019-10-11       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.